Roma Parikh

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Xavier Pivot, Alexey Manikhas, Zurawski Bogdan et al. · Journal of Clinical Oncology · 2015 · 248 citations · Full text

A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma

Christian Wülfing, Jean‐Pascal Machiels, D. J. Richel et al. · Cancer · 2009 · 213 citations · Full text

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

John Crown, H. A. Burris, Frances M. Boyle et al. · Breast Cancer Research and Treatment · 2008 · 97 citations

Gastrointestinal Oncology, Medicine, Cancer Management +8

An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer

Giuseppe Capri, José Chang, S.-C. Chen et al. · Annals of Oncology · 2009 · 86 citations · Full text

Metastatic Breast Cancer, Oncology, Breast Oncology +9

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy

Amit Gutwillig, Nadine Santana-Magal, Leen Farhat-Younis et al. · eLife · 2022 · 50 citations · Full text

Cell Therapy, Immunology, Immunoediting +18